ArticleFrontiers in medicine2025
Shenyuan granules improve cellular senescence through Klotho-mediated p16/p21 signaling pathway in diabetic kidney disease.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Shenyuan Granules (SYG), a traditional Chinese medicine preparation, are clinically used for treating chronic kidney diseases. However, the role of Klotho in modulating cellular senescence via the p16/p21 pathway and its involvement in the therapeutic effects of SYG in diabetic kidney disease (DKD) remains unclear. Objective: This study investigated the regulatory effects of SYG on the Klotho gene and their mechanisms in alleviating cellular senescence in DKD. Materials and methods: Utilizing an adenine-induced DKD model in Results: SYG treatment significantly improved renal function in db/db mice and alleviated histopathological lesions. SA- Discussion: This study highlights the potential of SYG to alleviate cellular senescence in DKD by targeting the Klotho-mediated p16/p21 pathway. These findings provide a foundation for developing senescence-focused therapies in chronic kidney disease management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.